On Friday, Hutchinson Technology Incorporated (NASDAQ:HTCH)’s shares declined -16.53% to $1.97.
Hutchinson Technology Incorporated (HTCH) stated a net loss of $9.7 million, or $0.29 per share, on net sales of $62.4 million, for its fiscal second quarter ended March 29, 2015. The net loss comprised of $430,000 of non-cash interest expense and a $140,000 foreign currency gain. Not taking into account these items, the company’s net loss for the fiscal 2015 second quarter was $9.4 million, or $0.28 per share.
In the preceding quarter, the company stated a net loss of $9.9 million, or $0.32 per share, on net sales of $72.4 million. The net loss comprised of a $4.3 million loss on debt extinguishment, $860,000 of non-cash interest expense, $640,000 of foreign currency losses and $160,000 of site consolidation costs. Not taking into account these items, the company’s net loss for the fiscal 2015 first quarter was $3.9 million, or $0.13 per share.
Hutchinson Technology Incorporated researches, designs, develops, manufactures, and supplies suspension assemblies for hard disk drives in Thailand, Hong Kong, the Philippines, Malaysia, the United States, and internationally.
Accuray Incorporated (NASDAQ:ARAY)’s shares dropped -16.17% to $6.82.
Accuray Incorporated (ARAY) declared that it has signed a contract with MIM Software Inc. to further develop adaptive therapy software for the TomoTherapy® and CyberKnife® product portfolios. The new software solution will leverage both Accuray and MIM technology. This is Accuray’s second partnershipwith MIM; the previous partnership led to the development of the first iPad-based treatment plan review capability, PlanTouch™.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
At the end of Friday’s trade, CytRx Corporation (NASDAQ:CYTR)‘s shares dipped -15.72% to $3.70.
CytRx Corporation (CYTR) stated financial results for the three months ended March 31, 2015, and offered an overview of recent accomplishments and forthcoming milestones for its clinical development programs.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.
Abaxis Inc (NASDAQ:ABAX), ended its Friday’s trading session with -13.31% loss, and closed at $55.48.
Abaxis Inc (ABAX) stated financial results for the fourth quarter and fiscal year ended March 31, 2015.
Fourth quarter and fiscal 2015 overview:
Revenues from ongoing operations of $52.0 million for the fourth quarter, up 33% over last year’s comparable quarter, and $202.6 million for fiscal 2015, up 25% year-over-year.
Revenues highlights:
North America revenues from ongoing operations for the fourth quarter of $41.8 million, up 39% over last year’s comparable quarter, and $163.3 million for fiscal 2015, up 29% year-over-year.
International revenues for the fourth quarter of $10.2 million, up 11% over last year’s comparable quarter, and $39.3 million for fiscal 2015, up 11% year-over-year.
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
